Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOMINIC JOHN TITONE

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1184816159
CMS profile
1109025
Location
LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$317.03

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $317.03 11

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOMINIC JOHN TITONE

NPI 1184816159 · CMS profile ID 1109025

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1184816159?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $317.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Inspire Medical Systems, Inc. $80.7311/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148118800 CMS
Actelion Pharmaceuticals US, Inc. $23.9610/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078873840 CMS
GlaxoSmithKline, LLC. $26.5007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116716093 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.2706/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117908362 CMS
GlaxoSmithKline, LLC. $25.3406/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116602107 CMS
Actelion Pharmaceuticals US, Inc. $24.8705/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078873846 CMS
GlaxoSmithKline, LLC. $23.3004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116395408 CMS
GlaxoSmithKline, LLC. $25.7903/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115967119 CMS
GlaxoSmithKline, LLC. $24.1403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116663715 CMS
GENZYME CORPORATION $18.5202/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139674260 CMS
Actelion Pharmaceuticals US, Inc. $18.6101/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078873862 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166.08 11
PY2020 $61.33 4
PY2021 $56.81 4
PY2022 $41.92 2
PY2023 $1,906.18 9
PY2024 $317.03 11
PY2025 $2,082.80 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $428,478.86 96
PY2024 Principal investigator $715,381.10 49
PY2023 Principal investigator $766,726.52 505

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,675.48 12/31/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1155803532
Principal investigator 1 ModernaTX, Inc. $4,059.11 12/02/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175325
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/02/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175327
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 11/26/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension No dispute reported 06/30/2026 1089692881
Principal investigator 1 Genentech, Inc. $135.00 11/13/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388918
Principal investigator 1 ModernaTX, Inc. $10,118.92 11/13/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175303
Principal investigator 1 Genentech, Inc. $9,539.00 10/23/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388858
Principal investigator 1 ModernaTX, Inc. $810.00 10/10/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147145570
Principal investigator 1 Chiesi USA, Inc. $250.00 10/09/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148224022
Principal investigator 1 ModernaTX, Inc. $14,036.96 10/09/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175301
Principal investigator 1 GlaxoSmithKline, LLC. $5,500.00 10/02/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519087
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 09/23/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519085
Principal investigator 1 Genentech, Inc. $150.00 09/20/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388844
Principal investigator 1 ModernaTX, Inc. $1,770.66 09/02/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147145504
Principal investigator 1 Mylan Specialty L.P. $5,500.00 08/26/2024 Non-covered Recipient Entity
Cognitive Clinical Trials
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407636
Principal investigator 1 Boehringer Ingelheim International GmbH $869.89 08/15/2024 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1101068165
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,275.28 08/15/2024 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Ph2 PoC in IPF No dispute reported 06/30/2026 1101073305
Principal investigator 1 Chiesi USA, Inc. $1,020.00 08/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148222120
Principal investigator 1 ModernaTX, Inc. $61,646.39 08/07/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175273
Principal investigator 1 ModernaTX, Inc. $7,250.00 08/07/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175281
Principal investigator 1 ModernaTX, Inc. $789.75 07/19/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147145210
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,500.00 07/17/2024 Non-covered Recipient Entity
Cognitive Clinical Trials
Ph2 PoC in IPF No dispute reported 06/30/2026 1101074935
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,500.00 07/03/2024 Non-covered Recipient Entity
Cognitive Clinical Trials
PhII - BI 1839100 in IPF associated with chronic cough No dispute reported 06/30/2026 1101068215
Principal investigator 1 Genentech, Inc. $7,047.00 07/03/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388850
Principal investigator 1 ModernaTX, Inc. $500.00 07/03/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147145202
Principal investigator 1 ModernaTX, Inc. $4,770.90 07/03/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175267
Principal investigator 1 Boehringer Ingelheim International GmbH $16,382.80 07/01/2024 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
PhII - BI 1839100 in IPF associated with chronic cough No dispute reported 06/30/2026 1101074921
Principal investigator 1 Genentech, Inc. $675.00 06/26/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388658
Principal investigator 1 Genentech, Inc. $750.00 06/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388650
Principal investigator 1 Genentech, Inc. $900.00 06/07/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,019.00 05/31/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1110848013
Principal investigator 1 ModernaTX, Inc. $600.00 05/22/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175257
Principal investigator 1 Genentech, Inc. $2,349.00 05/17/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388466
Principal investigator 1 Genentech, Inc. $750.00 05/17/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388542
Principal investigator 1 GlaxoSmithKline, LLC. $17,250.00 05/17/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127519089
Principal investigator 1 ModernaTX, Inc. $6,399.00 04/26/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175249
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,390.00 04/17/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1110848445
Principal investigator 1 ModernaTX, Inc. $184,339.38 04/05/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175247
Principal investigator 1 ModernaTX, Inc. $38,848.25 03/28/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147145310
Principal investigator 1 Chiesi USA, Inc. $10,320.00 03/27/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148217469
Principal investigator 1 Genentech, Inc. $270.00 03/27/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388396
Principal investigator 1 Genentech, Inc. $2,349.00 02/21/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388346
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,942.46 02/14/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110841896
Principal investigator 1 Genentech, Inc. $750.00 01/24/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133388388
Principal investigator 1 AstraZeneca Pharmaceuticals LP $64,922.37 01/17/2024 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1110841616
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $74,198.95 01/13/2024 Non-covered Recipient Entity
Cognitive Clinical Trials
Low Intervention Cough Monitoring Study in IPF and PPF No dispute reported 06/30/2026 1101071501
Principal investigator 1 ModernaTX, Inc. $1,340.00 01/10/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175231
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/10/2024 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1147175233
Principal investigator 1 Boehringer Ingelheim International GmbH $3,921.55 01/01/2024 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates
Low Intervention Cough Monitoring Study in IPF and PPF No dispute reported 06/30/2026 1101067681